Skadden, Arps, Slate, Meagher & Flom is advising Chinese smartphone maker Xiaomi on its upcoming initial public offering in Hong Kong, while Clifford Chance is counselling the joint sponsors CLSA, Goldman Sachs and Morgan Stanley.

Chinese firms JunHe and Jingtian & Gongcheng are acting as legal advisors to Xiaomi and the joint sponsors, respectively, on PRC law. Offshore firm Maples and Calder is also involved in the deal, advising the issuer on Cayman Islands law.

The IPO is expected to raise about $10 billion, making it the largest listing globally since Alibaba’s $25 billion New York listing in 2014. Xiaomi could list as early as the end of June, reported Reuters citing people close to the process who requested anonymity as the details were not yet public.

The Chinese smartphone maker said it would have a weighted voting rights (WVR) structure, or dual-class shares, and its listing will be the first in the city under new rules designed to attract tech listings, a major win for the bourse as competition heats up between Hong Kong, New York and the Chinese mainland.

Xiaomi is also likely to be among the first Chinese tech firms seeking a secondary listing in China, using the planned depositary receipts route, two people with knowledge of the matter told Reuters.

The Skadden team is led by partners Julie Gao and Christopher Betts, while the Clifford Chance team includes partners Tim Wang, Amy Lo, Jean Thio and Liu Fang.

Related Articles

金杜、汉坤、方达等助力“造车新势力”极氪4.41亿美元纽交所上市(ZH/EN)

5月10日,吉利旗下高端智能纯电动汽车品牌极氪在纽交所成功上市,募资金额约为4.41亿美元。这是近三年来最大的中概股美国IPO。

开年“扎堆”,内地茶饮企业或将引领今年的香港IPO市场(ZH/EN)

中国的新茶饮连锁店正在加速攻占中国一线城市和下沉市场的街头巷尾、百货商场。在资本市场,它们之间的争速则在另一个“战场”展开:港交所。

竞天公诚、方达领衔药明合联香港IPO,创当年度纪录(ZH/EN)

by Mari Iwata |

近日,药明合联于香港交所主板成功上市,成为今年迄今为止在香港的第三大IPO,以及最大医疗健康和生物科技IPO项目。